Inovio Q2 FY26 net loss narrows to $6.01 million; operating loss improves to $18.62 million
INO•Quarterly results
- Inovio posted a Q2 net loss of $6.01 million, narrowing from a $23.52 million loss a year earlier.
- R&D expense fell 25.41% to $10.83 million; G&A expense declined 8.9% to $7.8 million.
- Total operating expenses dropped 19.33% to $18.62 million, while operating loss narrowed to $18.62 million from $23.08 million.
Cash position and FDA timeline
- Cash, cash equivalents and short-term investments totaled $36.7 million at June 30, down from $58.5 million at Dec. 31.
- FDA review of the INO-3107 BLA advanced toward an Oct. 30, 2026 PDUFA date; cash runway was guided into late Q1 2027.
